Clinical trial
Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer
NCT00268593 · Progen Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00268593 |
|---|---|
| Title | Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer |
| Official title | A Randomised Phase II Study of Two Dose Schedules of PI-88 in Combination With Docetaxel in Patients With Androgen-independent Prostate Cancer |
| Lead sponsor | Progen Pharmaceuticals, Industry |
| Collaborators | Northern Sydney and Central Coast Area Health Service Aventis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | PI-88, docetaxel, prednisone |
| Enrollment | 48 |
| Start date | Aug 1, 2005 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Dec 22, 2005 |
| Last update posted | Jun 15, 2011 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: